[HTML][HTML] Hyperkalemia risk with finerenone: results from the FIDELIO-DKD trial
Background Finerenone reduced risk of cardiorenal outcomes in patients with CKD and type
2 diabetes in the FIDELIO-DKD trial. We report incidences and risk factors for hyperkalemia
with finerenone and placebo in FIDELIO-DKD. Methods This post hoc safety analysis
defined hyperkalemia as≥ mild or≥ moderate based on serum potassium concentrations
of> 5.5 or> 6.0 mmol/L, respectively, assessed at all regular visits. Cumulative incidences of
hyperkalemia were based on the Aalen–Johansen estimator using death as competing risk …
2 diabetes in the FIDELIO-DKD trial. We report incidences and risk factors for hyperkalemia
with finerenone and placebo in FIDELIO-DKD. Methods This post hoc safety analysis
defined hyperkalemia as≥ mild or≥ moderate based on serum potassium concentrations
of> 5.5 or> 6.0 mmol/L, respectively, assessed at all regular visits. Cumulative incidences of
hyperkalemia were based on the Aalen–Johansen estimator using death as competing risk …
